RET and neuroblastoma: Regorafenib is a multi-kinase inhibitor that targets VEGFRs, PDGFR, RET, RAF kinases, and other signaling molecules (50), suggesting that its impact on neuroblastoma cells may not be solely due to DHODH inhibition.